Structure of Class B GPCRs: new horizons for drug discovery

Citations Over TimeTop 10% of 2014 papers

Abstract

Class B GPCRs of the secretin family are important drug targets in many human diseases including diabetes, neurodegeneration, cardiovascular disease and psychiatric disorders. X-ray crystal structures for the glucagon receptor and corticotropin-releasing factor receptor 1 have now been published. In this review, we analyse the new structures and how they compare with each other and with Class A and F receptors. We also consider the differences in druggability and possible similarity in the activation mechanisms. Finally, we discuss the potential for the design of small-molecule modulators for these important targets in drug discovery. This new structural insight allows, for the first time, structure-based drug design methods to be applied to Class B GPCRs.

Related Papers

• → DREADDs: novel tools for drug discovery and development(2013)93 cited
• → Illuminating the understudied GPCR-ome(2023)13 cited
• → Structural genomics and drug discovery: all in the family(2008)43 cited
• → Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies(2019)23 cited
• → G Protein-Coupled Receptors(2007)4 cited